Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Mar;51(2):84-87.
Epub 2023 Mar 1.

BUPROPION MISUSE BY NASAL INSUFFLATION WITH A FATAL OUTCOME: CASE REPORT AND REVIEW

Sonia Pereira, Joao Simas, Pedro Mota, Paulo Carvalho  1 , Joao Pais
Affiliations
Case Reports

BUPROPION MISUSE BY NASAL INSUFFLATION WITH A FATAL OUTCOME: CASE REPORT AND REVIEW

Sonia Pereira et al. Actas Esp Psiquiatr. 2023 Mar.

Abstract

Bupropion is the only FDA - approved synthetic cathinone, with increasing popularity in clinical practice due to its wide range of action, and lack of sexual side effects. However, its stimulant effect similar to amphetamines has growing the concern regarding its recreational use.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

    1. Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51(3):293–313. - PubMed
    1. Saunders KH, Igel LI, Aronne LJ. An update on naltrexone/ bupropion extended-release in the treatment of obesity. Expert Opin Pharmacother. 2016;17(16):2235–42. - PubMed
    1. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195–202. - PubMed
    1. Niemegeers P, Dumont GJ, Patteet L, Neels H, Sabbe BG. Bupropion for the treatment of seasonal affective disorder. Expert Opin Drug Metab Toxicol. 2013;9(9):1229–40. - PubMed
    1. Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D. Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil. 2014;5:37–52. - PMC - PubMed

Publication types

MeSH terms

Substances